Marketing-authorisation holder
Shanghai Henlius Biotech, Inc.
7 medicines in 2 countries, as authorisation holder.
Group structure
Part of
HenliusPharmaceutical groupOther companies in the group
Headquarters not stated1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine in the registers under its name, current ones first.
7 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BILDYOS60 mg / ml · Solution | Denosumab | Canada | Authorised | |
| BILDYOS60mg/ml · Injectable | Denosumab | United States | Marketed | 2025 |
| BILDYOS60 mg / ml · Solution | Denosumab | Canada | Marketed | 2026 |
| BILPREVDA120mg/1.7ml(70mg/ml) · Injectable | Denosumab | United States | Marketed | 2025 |
| Bilprevda120mg/1.7ml (70mg/ml) · Injection | Denosumab | United States | Marketed | 2025 |
| POHERDY420mg/14ml(30mg/ml) · Injectable | Pertuzumab | United States | Marketed | 2025 |
| TUZEMTY120 mg / 1.7 ml · Solution | Denosumab | Canada | Marketed | 2026 |